Welcome to our dedicated page for Icu Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on Icu Medical stock.
ICU Medical reports news on its global medical-device business in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate-site and home-care settings. Company updates commonly cover quarterly results, fiscal guidance, GAAP and non-GAAP profitability measures, and revenue trends across the Consumables, Infusion Systems and Vital Care product lines.
Recurring announcements also include earnings-call schedules, investor conference participation and business changes that affect reported comparisons, including the completed divestiture of the IV Solutions business. The company’s news flow centers on product-line performance, margin trends, adjusted EBITDA, adjusted diluted earnings per share and management commentary on operating results.
ICU Medical (Nasdaq:ICUI) will release its second quarter 2021 financial results on August 4, 2021, at approximately 4:00 p.m. ET. A conference call will follow at 4:30 p.m. ET, accessible at (866) 248-8441 or via webcast on the company's website. ICU Medical specializes in innovative medical products for infusion therapy and critical care applications, with a comprehensive portfolio including IV smart pumps and cardiac monitoring systems. For more information, visit www.icumed.com.
ICU Medical, Inc. (Nasdaq:ICUI) reported its first-quarter 2021 financial results, revealing revenues of $318.0 million, down from $328.6 million in Q1 2020. The GAAP gross profit for the quarter fell to $112.7 million, yielding a 35% gross margin, compared to 37% the previous year. Despite this decline, GAAP net income increased to $23.7 million or $1.09 per diluted share, up from $16.8 million or $0.78 per diluted share in Q1 2020. Adjusted diluted EPS decreased to $1.62 from $1.81.
ICU Medical, Inc. (Nasdaq:ICUI) announced its first quarter 2021 earnings release scheduled for May 6, 2021, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call can be accessed via phone or streamed through the Company’s website. ICU Medical specializes in innovative medical products for infusion therapy and critical care, including IV smart pumps and cardiac monitoring systems. For more information, visit www.icumed.com.
ICU Medical, Inc. (Nasdaq:ICUI) will engage in a virtual fireside chat during the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2021, at 7:45 a.m. PT (10:45 a.m. ET). The chat will be streamed live on the company's website, and a replay will also be available. ICU Medical specializes in innovative medical products for infusion therapy and critical care, including IV smart pumps and safety software. The event aims to provide insights into the company’s advancements and market position.
ICU Medical (Nasdaq:ICUI) announced its fourth quarter 2020 financial results, reporting revenues of $320.5 million, up from $315.5 million year-over-year. The GAAP gross profit rose to $119.9 million with a gross margin of 37%. Net income reached $26.1 million or $1.21 per diluted share, compared to $20.6 million or $0.96 per share in Q4 2019. Adjusted diluted EPS decreased to $1.77 from $1.94. For 2021, the company projects adjusted EBITDA between $245 million and $265 million, and adjusted diluted EPS of $6.50 to $7.20.
ICU Medical, Inc. (Nasdaq:ICUI) announced its participation at the Raymond James 42nd Annual Institutional Investors Conference, taking place virtually from March 1-3, 2021. The company’s management will deliver a presentation on March 1, 2021, at 1:40 p.m. PST (4:40 p.m. EST). Investors can access the live webcast on the company's website under the Investors tab and the Event Calendar tab, with a replay available afterward. ICU Medical specializes in innovative medical products for infusion therapy and critical care applications.
ICU Medical, Inc. (Nasdaq:ICUI) has announced the schedule for its fourth quarter and fiscal year 2020 earnings release and conference call. The earnings report will be released on February 25, 2021, at approximately 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. Investors can access the call at (800) 936-9761 with conference ID 8029238 or via webcast on the company's website. ICU Medical specializes in innovative medical products for infusion therapy and critical care applications, helping to achieve clinical safety and workflow efficiency.
ICU Medical announced that its Plum 360 smart infusion system received the Best in KLAS honor as the top-performing Smart Pump EMR-Integrated. This recognition, a first by KLAS Research, highlights the Plum 360's alignment with industry guidelines for interoperable infusion systems. The award reflects feedback from thousands of healthcare professionals and emphasizes ICU Medical's leadership in infusion therapy. The company aims to enhance safety through improved integration with electronic medical records (EMR) and other systems, demonstrating a commitment to innovation and customer satisfaction.
ICU Medical (Nasdaq:ICUI) announced its participation in the J.P. Morgan 39th Annual Healthcare Conference, taking place virtually from January 11-14, 2021. The company's presentation is scheduled for January 13, 2021, at 8:40 a.m. PST (11:40 a.m. EST).
The event will be webcast live, accessible via the ICU Medical website under the Investors tab. The presentation will also be available for replay.
ICU Medical, Inc. (Nasdaq:ICUI) reported Q3 2020 revenues of $318.6 million, a $11.1 million increase year-over-year. However, GAAP gross profit declined to $113.9 million with a gross margin of 36%, down from 39% in Q3 2019. Net income was $25.0 million, or $1.16 per diluted share, down from $26.6 million or $1.24 per share in the same quarter last year. Adjusted EPS rose to $1.90 from $1.65. The company narrowed its 2020 adjusted EBITDA outlook to $235-$245 million and updated EPS guidance to $6.65-$7.00.